MOL #59865
Dopamine and serotonin, as opposed to emerging interest in glutamate, played a dominant role during the formative years of modern psychopharmacology when thinking about the pathophysiology and or treatment of schizophrenia. Models derived from studying the behavioral effects of amphetamine and serotonergic hallucinogens were emphasized (see Table 1 ). The seminal observations by Arvid Carlsson and his colleagues in the late early 1960's which first postulated functional dopamine receptor blockade as a necessary therapeutic action by the phenothiazine and butyrophenone structural classes set the stage for our current mechanistic understanding of all antipsychotic drugs currently used today (Carlsson and Lindquist, 1963) . The emergence of in vitro receptor binding and PET receptor occupancy studies in healthy volunteers and patients identified dopamine D2 receptor blockade as a critical feature for antipsychotic drugs in the clinic (Creese et al., 1976; Farde et al., 1988; Seeman et al., 1976) . The early identification of dopamine D2 receptor binding sites by Seeman and Snyder in the 1970s and correlating antipsychotic efficacy to dopamine D2 receptor binding, prior to cloning of the D2-like family of dopamine receptors, further enriched the understanding for the molecular target which all antipsychotic drugs share in common (Creese et al., 1976; Seeman et al., 1976) . Blockade of 5-hydroxytryptamine 2A receptors was an important molecular target complimenting blockade of dopamine D2 receptors for the development of atypical antipsychotic drugs (Kapur et al., 1999; Meltzer et al., 1989) . and treatment of schizophrenia (Krystal et al., 1999; Luby et al., 1959; Tamminga, 1998) .
The initial hypothesis of glutamatergic hypofunction was strongly influenced by neuroimaging studies suggesting cortical hypofunction during rest or the performance of cognitive tasks. Later, the non-competitive NMDA receptor antagonists were found preferentially increase metabolism and extracellular glutamate levels in defined limbic circuits rather than over the entire cortical manner (Duncan et al., 1999; Holcomb et al., 2005; Lahti et al., 1995; Moghaddam et al., 1997) .
Thus, these studies suggested that subanesthetic doses of non-competitive NMDA receptor antagonists were activating glutamatergic neurons in the cerebral cortex and hippocampus; the glutamate released by these neurons could activate other ionotropic glutamate receptors (AMPA and kainate) or metabotropic glutamate (mGlu) receptors.
While these studies do not support a general notion that glutamate function or NMDA receptor function is necessarily decreased everywhere in the schizophrenic brain, the hypothesis remains that impaired NMDA function in important cellular compartments of the limbic forebrain may be a critical feature underlying the pathophysiology of schizophrenia. The variability from neuroimaging studies describing hyperactivation as well as hypoactivation in the brains of schizophrenic patients compared to healthy volunteers suggest that the brain from a schizophrenic patient is more aptly characterized by dysfunctional circuitry rather than simply increased or decreased activity (Callicott et al., 2003) .
Concurrently with the notion of a dysfunctional circuitry, the hypothesis that schizophrenia might be a neurodevelopmental disorder gained prominence as a variety of neuroimaging modalities indicated that substantial changes may be present even prior to MOL #59865 6 initial treatment. The magnetic resonance imaging (MRI) diffusion tensor imaging (DTI) studies (Ellison-Wright and Bullmore, 2009) were especially important as they highlighted substantial abnormalities in long-loop tracts such as thalamocortical pathways that were consistent with histopathological studies defining a diminished neuropil in the prefrontal cortex and loss of cells in a number, though not all, thalamic stereology studies. In addition to suspected developmental defects in these long-loop pathways connecting the prefrontal cortex, thalamus, striatum, hippocampus, amygdala and dopamine-containing brainstem neurons, a better understanding a local circuit defects in schizophrenia has also emerged. Thus, currently investigators work within the framework that schizophrenia involves dysfunctional local and long-loop network activity rather than there being simply decreased glutamatergic NMDA receptor tone in the brain (Tan et al., 2007 (Ford and Mathalon, 2008; Gonzalez-Burgos and Lewis, 2008) . Alternately, dysinhibition of local circuits in areas projecting to crucial limbic circuitry such as hippocampal-prefrontal cortical pathways could account for an increase in activity in the PFC following the acute administration of noncompetitive NMDA receptor antagonists. For schizophrenia again, hypofunction of NMDA receptors at various nodes within these micro-and macrocircuits may contribute to disturbances of gamma oscillations leading to disturbances of cognition, affect and bizarre delusions and hallucinations (Roopun et al., 2008) . The importance of glutamate and NMDA receptors during normal CNS development is likely to play an important mechanistic role in the neurodevelopmental hypothesis of schizophrenia.
The clinical report that a mGlu2/3 receptor agonist prodrug effectively treated both positive and negative symptoms of schizophrenia patients from a multi-center, double-blind, placebo-controlled study (Patil et al., 2007) is significant for at least several reasons. First, this is the first non-dopamine D2 receptor based treatment that has produced an apparently robust antipsychotic effect. Secondly, the primary effect of activating mGlu2 receptors involves stimulation of an autoreceptor with a limbic localization in many of the regions suspected to be involved in the pathophysiology of schizophrenia (prefrontal cortex, dorsal and ventral striatum, thalamus, hippocampus, amygdale, see Fig. 1 , (Ghose and Tamminga, 2007) ). Thus, activation of mGlu2 receptors would be expected to decrease glutamate release from excitatory amino acid containing axons/nerve terminals as shown in Fig. 2 (Schoepp, 2001 ).
This article has not been copyedited and formatted. The final version may differ from this version. In this minireview we will review evidence that modulating glutamate in dysfunctional limbic circuits may be an important strategy opening up new molecular targets for the treatment of schizophrenia. The discussion first will center around orthosteric mGlu2/3 receptor agonists or mGlu2 receptor positive allosteric modulators (PAMs). The last two targets that will be exemplified will be those that might address hypofunctional NMDA receptor in the miswired dysfunctional limbic circuits, inhibitors of the glycine transporter 1 subtype and mGlu5 receptor PAMs.
mGlu2/3 receptor agonists
It has been more than ten years ago that the first studies using selective mGlu2/3 receptor agonists convincingly demonstrated antipsychotic-like potential of such agents Homayoun and Moghaddam, 2008) .
Increased cortical glutamate release is likely to account for the ability of systemic administration of PCP-like agents (such as MK-801) to increase the spontaneous firing rate of prefrontal cortical neurons, to decrease the variability of spike trains, and disrupt patterns of spontaneous bursting. Stimulation of mGlu2/3 receptors was shown to reverse these effects (Homayoun et al., 2005) , a finding that is well in line with the results of neurochemical studies.
At the first glance, enhanced glutamatergic activity and increased firing rate of cortical neurons after acute NMDA receptor channel blockade do not fit well with the This article has not been copyedited and formatted. The final version may differ from this version. views on hypofrontality in schizophrenia. Indeed, there are several reports on enhanced activity of brain areas involved in pathophysiology of schizophrenia under conditions of limited cognitive load. For example, one study found greater activation in the hippocampus, thalamus, and dorsolateral prefrontal cortex in patients with schizophrenia during the sensory gating task as well as in response to urban noise (Tregellas et al., 2007; Tregellas et al., 2009 ) while another group reported on elevated hippocampal and amygdala activity during the passive viewing of human faces (Holt et al., 2006) .
However, when the behavioral performance sets additional demands on these networks, activity will increase further and such above-physiological increase will now be accompanied by abnormally high or lost synchronization, phenomena also observed after acute application of sufficiently high doses of PCP-like drugs (Pinault, 2008; Sebban et al., 2002) . Such synchronization is seen as a potential facilitator of neural communication and synaptic plasticity. For the tasks, commonly used to study hypofrontality (e.g., working memory tasks), synchronized network activity is very critical as it favors information retention via increased activity of certain ensembles of neurons. Decorrelated or desynchronized activity may functionally be expressed as hypofrontality.
Another hypothetical approach to look at the relationships between neuronal activity and functional performance is best represented by the analysis of dopaminergic modulation of working memory and prefrontal cortical activity. It is currently believed that there is a certain level of dopamine receptor stimulation (more specifically, D1 receptors) that is required for optimum performance (Arnsten, 1998) . Both reduced and increased dopamine receptor stimulation result in impaired cognitive performance. In
This article has not been copyedited and formatted. The final version may differ from this version. other words, there is an inverted U-shaped relationship between cortical activity and cognitive performance. These studies led further to explain existence of both hyper-and hypofrontality states in schizophrenia patients. Callicott and colleagues (2003) suggested that schizophrenia is associated with the leftward shift in the inverted U function compared to healthy control subjects. At low working memory load, patients are thus expected to appear hyperfrontal. However, their working memory capacity is eventually breached that results in a hypofrontal pattern.
Interestingly enough, cognitive effects of mGlu2/3 receptor agonists may also follow a biphasic dose-effect function. There were reports that acute systemic application of selective mGlu2/3 receptor agonists such as LY354740 impairs performance in cognitive tasks in laboratory animals (Higgins et al., 2004) . Following the inverted U-shaped activity-performance function hypothesis outlined above by Callicott and colleagues (2003) , one could speculate that the impairing effects of mGlu2/3 receptor agonists are more likely to be observed under somewhat challenging conditions that require a significant increase in cortical activity but still result in proper cognitive performance. In contrast, one may expect then that lower-demand cognitive tasks may fail to detect impairing effects of mGlu2/3 receptor agonists. Perhaps, this explains why no cognitive-impairing effects of LY354740 were observed in humans where tasks may have been optimized to study cognitive impairments produced by ketamine (Krystal et al., 2005) .
Within the inverted U hypothesis, it presents no difficulty to understand how a compound that may impair cognition when given alone, is able to reverse cognitive deficits induced by another agent. 
demonstrated that
This article has not been copyedited and formatted. The final version may differ from this version. A study by explicitly linked reversal of PCPinduced cognitive impairment with the ability of LY354740 to attenuate PCP-induced cortical glutamate release. Taken together with other work from this and other groups, these data suggest that mGlu2/3 receptor stimulation may reverse this excessive release of glutamate, restore normal neuronal activity and thereby improve cognitive performance.
The only known clinical laboratory study on cognitive effects of mGlu2/3 receptor stimulation in humans directly supports these expectations. Krystal and coworkers (2005) reported that LY354740 induced a dose-dependent reversal of ketamineThis article has not been copyedited and formatted. The final version may differ from this version. Further regarding the effects of mGlu2/3 receptor agonists on cognition in humans, LY354740 and the prodrug LY544344 did not induce adverse events suggesting cognitive impairment in over 450 patients with generalized anxiety disorder where this mGlu2/3 receptor agonist and prodrug where found to produce therapeutic effects (Dunayevich et al., 2008; Michelson et al., 2005) .
First support for these predictions relative to schizophrenic patients is provided by the results of a recent clinical study where the mGlu2/3 receptor agonist LY404039
(administered as a prodrug known as LY2140023) reduced PANSS total, positive and negative scores in patients with schizophrenia (Patil et al., 2007) . Effects of LY2140023 on cognition were not assessed in this study. However, one may want to note that, in the Patil study, there were two cognition-related PANSS items (difficulty in abstract thinking and poor attention) that were reportedly positively affected by mGluR2/3 agonist treatment (communicated by A. Breier at 46 th ACNP meeting, 9-13 December 2007).
While effects of mGlu2/3 receptor agonists on cognition in schizophrenia patients await This article has not been copyedited and formatted. The final version may differ from this version. more formal evaluation, these preliminary data may be taken as the first evidence confirming the expectations generated by the results of preclinical studies (Table 1) .
Further confirmatory studies will be required to understand the therapeutic efficacy effect size for LY2140023, especially compared to aripiprazole, quetiapine, and ziprasidone.
These atypical antipsychotic drugs, unlike olanzpaine and risperidone, have not been found to provide a clinically significant benefit with respect to treating the positive and negative symptoms of schizophrenia over the first generation of antipsychotic drugs when compared in the CATIE studies or meta-analyses.
One important question of relevance for ongoing and future drug discovery efforts is the mGlu receptor subtype mediating the therapeutic effects of LY2140023 in patients.
Genetic association analyses have been consistently pointing at single-nucleotide polymorphisms in the mGlu3 receptor gene (GRM3) in several populations of schizophrenia patients. This GRM3 polymorphism is associated with a non-coding region that does not appear to affect mGlu3 receptor expression outside of a single report suggesting altered levels of mGlu3 receptor homodimers (Corti et al., 2007) . However, detailed studies conducted by Weinberger and colleagues suggested a specific molecular pathway by which GRM3 genotype alters glutamate neurotransmission, prefrontal and hippocampal physiology and cognition, and thereby increased risk for schizophrenia (Egan et al., 2004) . More specifically, these studies revealed a link between a high-risk GRM3 allele and reduced expression of glial glutamate transporter. While there is not much further evidence in support of this hypothesis, a genetic silencing of glial transporter expression in mice resulted in the behavioral abnormalities that are typically observed after the treatment with psychotomimetic drugs (Karlsson et al., 2008) . The
This article has not been copyedited and formatted. The final version may differ from this version. agonist with demonstrated antipsychotic activity in the clinic, lose the ability to attenuate behaviors induced by psychotomimetic drugs when tested in mGlu2, but not mGlu3, knockout mice Spooren et al., 2000; Woolley et al., 2008) .
mGlu2 receptor potentiators (e.g., PAMs)
Another growing body of evidence supporting the significance of mGlu2 receptors in the antipsychotic effects of orthosteric mGlu2/3 receptor agonists comes from a number of studies that demonstrated comparable efficacy of mGlu2 receptor PAMs Johnson et al., 2005 frequency-dependent modulation of synaptic transmission in the striatum . Such ability to "recognize" pathological state(s) and/or networks could result in improved therapeutic efficacy and safety.
Available evidence appears to support such a profile of mGlu2 receptor PAMs.
On the one hand, there are no signs that these drugs produce any cognitive impairment in normal subjects. This is an important phenomenon to consider because of the knockout mouse data that specifically implicated mGlu2 receptors in cognitive-impairing effects of mGlu2/3 receptor agonists (Higgins et al., 2004) . On the other hand, mGlu2 receptor potentiators reproduce both antipsychotic-like (Table 1) and anxiolytic-like effects of mGlu2/3 receptor agonists Johnson et al., 2005) . Currently, there is much less information available to claim that positive allosteric modulation of mGlu2 receptors would be sufficient to overcome cognitive impairments associated with acute NMDA receptor channel blockade by PCP-like drugs or with glutamatergic dysbalance associated with schizophrenia. With several research groups actively working in this field and a number of fairly potent compounds already known, characterization of the cognitive effects of selective mGlu2 receptor potentiators will certainly be completed soon.
GlyT1 inhibitors
Among the approaches aiming at the reversal of a suspected NMDA receptor hypofunction in schizophrenia activation of the glycine-site represents the most direct cycloserine, a partial agonist of the glycine site, and with sarcosine, a naturally occurring low affinity glycine transport inhibitor. Across studies the full agonists were more effective than the partial agonist D-cycloserine and the tested compounds were more efficacious in conjunction with typical and newer atypical antipsychotics than with clozapine (Javitt, 2008) . The latter outcome has been attributed to a putative intrinsic component of clozapine enhancing glutamatergic neurotransmission (Coyle, 2006) . The most prominent effect across all trials was an improvement of negative symptoms by 15 % (Javitt, 2008) . Positive and cognitive symptoms were significantly improved in some but not all trials. Due to the small number of patients recruited in these trials and the negative outcome of one large multi-center trial, the CONSIST study (Buchanan et al., 2007) , the trials do not allow a final conclusion about the clinical effectiveness of NMDA glycine-site activation. A key problem in the interpretation of the results is the uncertainty whether appropriate brain concentrations, and more importantly, synaptic levels of the glycine site agonists have been achieved. To obtain a more efficient increase of synaptic glycine and hence NMDA receptor activation, high affinity inhibitors of the glycine transporter 1 (GlyT1) are currently being developed by several pharmaceutical companies.
GlyT1 shows a widespread distribution throughout the brain. In the cerebellum and caudal parts of the CNS GlyT1 appears to be predominantly localized on glial cells and to be involved in the regulation of inhibitory glycinergic neurotransmission (Zafra and Gimenez, 2008) , while in the forebrain it has been localized pre-and postsynaptically at glutamatergic synapses. At the molecular level, physical association with synthaxin 1A
and with PSD95, an NMDA receptor-associated protein indicates a synaptic localization This article has not been copyedited and formatted. The final version may differ from this version. were shown to increase extracellular glycine levels in the cortex Depoortere et al., 2005) and hippocampus of freely moving rats and to enhance NMDA receptor activity Depoortere et al., 2005; Martina et al., 2004) . The results correspond to increases of NMDA receptor-mediated currents in heterozygous GlyT1 knockout mice as well as forebrain selective homozygous GlyT1 knockout mice (Tsai et al., 2004; Yee et al., 2006) . Apart from enhancing synaptic activity GlyT1 inhibition also increased LTP in line with the role NMDA receptors in synaptic plasticity . Together the data support the validity of the concept to enhance NMDA receptor activity by GlyT1 inhibition.
Preclinical antipsychotic-like effects of GlyT1 inhibitors are described in an increasing number of publications which can only in part be summarized in this review (Table 1) .
Several compounds have been reported to antagonize the hyperlocomotion induced by PCP or MK-801 Depoortere et al., 2005; Harsing et al., 2003; Singer et al., 2009) . In adult rats treated with PCP at neonatal age the enhanced locomotor response to amphetamine could be reversed . The attenuation of locomotor responses may, at least in part, be mediated via an effect on dopaminergic neurotransmission. GlyT1 inhibitors have been reported to inhibit PCP and methamphetamine-induced (Drescher et al., 2006) (Drescher, personel communication) and ethanol-induced (Molander et al., 2007) dopamine release in the nucleus accumbens, This article has not been copyedited and formatted. The final version may differ from this version. whereas basal dopamine in the PFC was increased . In chronically PCP-treated rats the increased sensitivity of the DA release as well as the locomotor response to amphetamine could be reversed by GlyT1 inhibition (Javitt et al., 2004) . These results indicate the capability to reverse evoked or sensitized mesolimbic hyperdopaminergic states and to increase basal dopamine in the PFC suggesting a beneficial effect on positive symptoms associated with imbalanced dopaminergic activity.
Support for efficacy against positive symptoms comes also from the reported reversal of amphetamine-disrupted latent inhibition (Black et al., 2009) , a model thought to reflect increased salience and distractibility associated with psychotic symptoms.
By increasing dopamine in the PFC in conjunction with an expected enhancement of NMDA receptor activity, GlyT1 inhibitors are believed to reverse dysfunctional PFCsubcortical circuitry associated with negative symptoms. In support of potential efficacy against negative symptoms we have observed the attenuation of PCP-induced social interaction deficits by different GlyT1 inhibitors (data not shown). Furthermore the two GlyT1 inhibitors SSR103800 and SSR504734 were found to reverse abnormally persistent latent inhibition induced by MK801 (Black et al., 2009 ) which has been linked to impaired set shifting associated with negative symptoms (Weiner, 2003) .
Since the latter model is also thought to reflect cognitive inflexibility the results point to the ability of GlyT1 inhibition to re-instate cognitive flexibility. Several other effects of GlyT1 inhibitors in the cognitive domain have been reported. SSR103800 and NFPS (Karasawa et al., 2008) reversed object recognition impaired by acute or chronic NMDA receptor antagonists; SSR504734 reversed impaired social discrimination in rats treated with PCP at neonatal age (Harich et al., 2007) and This article has not been copyedited and formatted. The final version may differ from this version. SSR504734 enhanced working memory performance in a continuous delayed alternation task in C57BL/6 mice ). These effects are of relevance for improving cognition in schizophrenia since these models reflect particular schizophrenia-related cognitive deficits such as impaired visual object memory, face recognition memory (Calkins et al., 2005) and working memory. Altogether, available data describe a broad antipsychotic-like profile of GlyT1 inhibitors promising efficacy across different symptoms in schizophrenia. Little is known about the cells or circuits mediating the reported effects. Numerous examples of GlyT1 inhibitors antagonizing effects of NMDA receptor antagonists suggest that GlyT1 inhibitors may affect cells which exhibit a particular sensitivity for NMDA receptor antagonists. An intriguingly selective PCP antagonistic effect was recently reported for SSR504734, which completely and selectively reversed the pattern of brain activation by PCP in a phMRI study (Gozzi et al., 2008) . The most plausible explanation for this observation is the reversal of reduced NMDA receptor activity at GABAergic interneurons suspected to have a particular sensitivity for a blockade by non-competitive NMDA receptor antagonists (Coyle, 2004) .
The re-instatement of impaired NMDA receptor activity at interneurons (but not necessarily selectively at interneurons) may be fundamental for the antipsychotic activity of GlyT1 inhibitors. It was shown in a recent study that the expression of the GluN2A (NMDA NR2A subunit) in GAD67 positive cells in layer 2 and 5 of the cingulate cortex of subjects with schizophrenia is dramatically reduced by more than 50% (Woo et al., 2008) . The reduced GluN2A expression is likely due to a reduced NMDA receptor activity at the affected interneurons since it has been shown in other studies that GluN2A expression appears to be downregulated by reduced glutamatergic input and vice versa.
This article has not been copyedited and formatted. The final version may differ from this version. In line with this assumption subchronic treatment with MK-801 has been shown to almost completely downregulate the expression of NMDA receptor subunits and parvalbumin in microdissected parvalbumin positive interneuron in the rat frontal cortex (Xi et al., 2009 ). Whether GlyT1 inhibition is able to enhance NMDA receptor expression in GABAergic interneurons needs to be demonstrated.
There have been concerns that GlyT1 inhibition may be associated with unwanted side effects, in particular with motor impairments and respiratory effects mediated via activation of glycine A receptors in the cerebellum and in the brainstem. It is important to note that these concerns are based on effects of a subclass of GlyT1 inhibitors, which contain a sarcosine moiety in their structure. It has been shown that sarcosine-derived inhibitors exhibit an allosteric and irreversible inhibition while non-sarcosine-derived structures were found to be reversible competitive inhibitors (Mezler et al., 2008) .
Consistent with an irreversible inhibition, sarcosine-derived inhibitors produce slowly increasing and sustained locomotor impairments (Perry et al., 2008) 
mGlu5 receptor potentiators
The mGlu5 receptor mRNA and protein is distributed widely throughout the limbic forebrain (e.g., cortex, hippocampus, dorsal and ventral striatum) with a relatively sparse distribution in much of the brainstem (Abe et al., 1992; Romano et al., 1995) . (Muly et al., 2003) and hippocampal formation (Kerner et al., 1997) . A numerically minor cellular compartment where mGlu5 receptors are also found are in axons of presumed glutamatergic neurons where they may enhance glutamate release in the prefrontal cortex and neocortex (Marek and Zhang, 2008; Muly et al., 2003; Musante et al., 2008; Romano et al., 1995; Thomas et al., 2000) .
This article has not been copyedited and formatted. The final version may differ from this version. Homer1 proteins may play a regulatory role in targeting mGlu5 receptors to axonal or dendritic compartments (Ango et al., 2000) .
Amongst the effects seen in mice with a deletion of the mGlu5 receptor, sensorimotor gating as reflected by prepulse inhibition was disrupted in using several mice knockout strains with different backgrounds (Brody et al., 2004b) . Neither clozapine nor haloperidol reversed the prepulse inhibition deficit in the mGlu5 receptor -/-strain at doses which were active in reversing either amphetamine-or ketamineinduced deficits in wild type mice (Brody et al., 2004a) . The effects of mGlu5 receptor
PAMs in animals and mGlu5 receptor negative allosteric modulators in man described below, however, suggest caution in over-interpreting data with transgenic mice lines.
For both the group I (mGlu1 and mGlu5) and group II (mGlu2 and mGlu3) mGlu receptors, the development of selective agonists within a group with appropriate drug-like properties has been very difficult. potentiation of mGlu5 receptor function in hippocampal slices (O'Brien et al., 2004) .
Both in vitro and in vivo studies supporting utility in treating cognitive dysfunction may be found in a recent report that the mGlu5 receptor PAMs facilitated both hippocampal long-term potentiation and long-term depression in addition to enhancing performance in the Morris water maze (Ayala et al., 2009) . Additional evidence for a pro-cognitive effect of mGlu5 receptor PAMs was found in attenuation of performance impairments induced by MK-801 on a operant set-shifting task when a mGlu5 receptor PAM was administered following the channel blocking NMDA receptor antagonist (Darrah et al., 2008) . The Addex mGlu5 receptor PAM ADX47273 was also reported to attenuate natural or scopolamine-induced forgetting in the novel object recognition task (EppingJordan et al., 2005) .
Further evidence consistent with antipsychotic action for mGlu5 receptor PAMs has been collected for different chemical platforms originating from Merck and Addex scientists, respectively, using classical antipsychotic screening tests (Table 1) . For example, CDPPB and/or ADX47273 have been found to suppress amphetamine-induced hyperactivity or amphetamine-induced deficits in prepulse inhibition in rats (EppingJordan et al., 2005; Kinney et al., 2005; Liu et al., 2008) . Several different mGlu5
receptor PAMs have also been reported to attenuate locomotor hyperactivity induced by channel blocking NMDA receptor antagonists Homayoun and Moghaddam, 2008; Liu et al., 2008) effect in a classical screen by reducing conditioned avoidance responding in the rat .
While mGlu5 receptor PAMs have not yet reached phase 2 proof-of-concept testing in patients, a putative anxiolytic drug, fenobam, was investigated in phase 2 trials that was subsequently determined to be a selective mGlu5 receptor NAM (Porter et al., 2005) . While there was modest clinical evidence for an anxiolytic effect of fenobam in patients, is was discontinued after this medication appeared to induce derealization and depersonalization in patients with anxiety disorders. While these observations may portend positive effects for mGlu5 receptor PAMs in the clinic for schizophrenia, it still remains unknown if these adverse events were due to the pharmacology of the parent molecule.
Many questions remain for this target. What symptom domains of schizophrenia will mGlu5 PAMs effectively treat? Which cellular locus of action(s) will be responsible for these effects? If mGlu5 receptor PAMs are effective in treating schizophrenia, will these effects be related to coupling of mGlu5 receptors with NMDA receptors through scaffolding proteins or will they be independent of this physiological coupling?
Conclusions
Over the last 25 years, hypotheses reflecting glutamate hypofunction and then later NMDA receptor hypofunction in schizophrenia have been reinterpreted by the growing recognition that this pathophysiological principle acts within the context of dysfunctional local circuits and miswired long-loop pathways between the prefrontal cortex, hippocampus, striatum, thalamus, amygdala, and the ventral tegmental area. A This article has not been copyedited and formatted. The final version may differ from this version. expected that better understanding the nature by which ensembles of neurons lead to oscillatory behavior both within a given region and between cortical and subcortical regions will help us optimize glutamatergic treatments for schizophrenia. It is also hoped that such translational work between rodents, non-human primates and humans will also lead to additional breakthroughs to treat this devastating illness.
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